RU2009107123A - Способы и фармацевтические препараты, способствующие лечению индуцированной химиотерапией нейропатии - Google Patents

Способы и фармацевтические препараты, способствующие лечению индуцированной химиотерапией нейропатии Download PDF

Info

Publication number
RU2009107123A
RU2009107123A RU2009107123/15A RU2009107123A RU2009107123A RU 2009107123 A RU2009107123 A RU 2009107123A RU 2009107123/15 A RU2009107123/15 A RU 2009107123/15A RU 2009107123 A RU2009107123 A RU 2009107123A RU 2009107123 A RU2009107123 A RU 2009107123A
Authority
RU
Russia
Prior art keywords
pharmaceutical preparation
cisplatin
specified
treatment
lethrin
Prior art date
Application number
RU2009107123/15A
Other languages
English (en)
Russian (ru)
Inventor
Гуру РЕДДИ (US)
Гуру РЕДДИ
Дорла МИРЕЙОВСКИ (US)
Дорла МИРЕЙОВСКИ
Луиджи ЛЕНАЗ (US)
Луиджи ЛЕНАЗ
Original Assignee
Спектрум Фармасьютикалз, Инк. (Us)
Спектрум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Спектрум Фармасьютикалз, Инк. (Us), Спектрум Фармасьютикалз, Инк. filed Critical Спектрум Фармасьютикалз, Инк. (Us)
Publication of RU2009107123A publication Critical patent/RU2009107123A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009107123/15A 2006-08-01 2007-08-01 Способы и фармацевтические препараты, способствующие лечению индуцированной химиотерапией нейропатии RU2009107123A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
US60/821,082 2006-08-01

Publications (1)

Publication Number Publication Date
RU2009107123A true RU2009107123A (ru) 2010-09-10

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009107123/15A RU2009107123A (ru) 2006-08-01 2007-08-01 Способы и фармацевтические препараты, способствующие лечению индуцированной химиотерапией нейропатии

Country Status (12)

Country Link
EP (1) EP2046335A2 (enExample)
JP (1) JP2009545619A (enExample)
KR (1) KR20090047501A (enExample)
CN (1) CN101657199A (enExample)
BR (1) BRPI0715504A2 (enExample)
CA (1) CA2659477A1 (enExample)
IL (1) IL196824A0 (enExample)
MX (1) MX2009001116A (enExample)
NO (1) NO20090279L (enExample)
RU (1) RU2009107123A (enExample)
WO (1) WO2008017000A2 (enExample)
ZA (1) ZA200900728B (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
BRPI0715504A2 (pt) 2014-05-06
EP2046335A2 (en) 2009-04-15
IL196824A0 (en) 2009-11-18
MX2009001116A (es) 2009-02-10
CA2659477A1 (en) 2008-02-07
KR20090047501A (ko) 2009-05-12
WO2008017000A3 (en) 2008-03-20
WO2008017000A8 (en) 2009-04-30
ZA200900728B (en) 2010-03-31
CN101657199A (zh) 2010-02-24
NO20090279L (no) 2009-02-26
JP2009545619A (ja) 2009-12-24
WO2008017000A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
CN1222294C (zh) 含吗啉蒽环类衍生物和抗癌剂的联合制剂
AU2002343548B2 (en) Improved use of antitumoral compound in cancer therapy
RU2428982C2 (ru) Применение соединения
JP2005008534A (ja) 抗癌剤及び癌の治療方法
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
EP2023931A2 (en) Anticancer treatments with a combination of docetaxel and ecteinascidin
Kobayashi et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
CN109498627A (zh) 一种治疗肿瘤的药物组合物及其应用
CN1254279A (zh) 治疗卵巢癌的方法和组合物
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
US20030133994A1 (en) Method for treating cancer having greater efficacy and reduced adverse effects
RU2010121882A (ru) Новая композиция для лечения побочных эффектов противораковой терапии
CN100346794C (zh) 制备用于降低抗癌药物毒性的药剂的用途
CN109419773B (zh) 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用
Ninomiya et al. Multicenter phase II trial of combination chemotherapy with weekly paclitaxel and 5-fluorouracil for the treatment of advanced or recurrent gastric carcinoma
ES2774101T3 (es) Cabazitaxel y su uso para tratar cáncer
KR20070089158A (ko) 암의 치료를 위한ｎ-(3-메톡시-5-메틸피라진-2-일)-2-(4-[1,3,4-옥사디아졸-2-일]페닐)피리딘-3-설폰아미드 및 항-유사분열제의 조합물
Satıcı et al. Non-small Cell Lung Cancer: Systemic Chemotherapy for NSCLC
Parikh et al. Treatment of Extensive-Stage Small Cell Lung Cancer
WO2009104152A1 (en) Combination treatment for ovarian cancer
JP2009545619A5 (enExample)
IL283442B2 (en) Synergistic preparations containing r-2-(converted sulfonyl)-hexahydro-pyrrolo[2,1-a]pyrazin-6(2h)-ones and s-2-(converted sulfonyl)-hexahydro-pyrrolo[2,1-a]pyrazin-6(2h)-ones in a non-racemic ratio
RU2019135507A (ru) Фармацевтическая комбинация для лечения рака
Hanauske Recent advances in anticancer drug development

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20101014